Top Markets
Coin of the day
Oncotelic Therapeutics, Inc. Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics, Inc.

OTLC
Rank in Stocks #30394
Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage... Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage biopharmaceutical company, specializes in developing therapeutics for rare oncological conditions. Its flagship therapeutic candidate, OT-101 – an antisense compound designed to inhibit TGF-ß2 – is currently undergoing Phase 3 clinical trials for both pancreatic cancer and glioblastoma. Beyond oncology, OT-101 is also being explored for its potential in treating various viral diseases, including severe acute respiratory syndrome (SARS) and coronaviruses. The company's pipeline further includes OXi4503, which is being advanced for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and CA4P, intended for the treatment of advanced metastatic melanoma.
Share Price
$0.03834
Last synced: 2026-08-18
Market Cap
$17.01M
Change (1 day)
-4.15%
Change (1 year)
-24.82%
Country
US
Trade Oncotelic Therapeutics, Inc. (OTLC)

Category

P/B ratio for Oncotelic Therapeutics, Inc. (OTLC)
P/B ratio as of 2026 TTM: 0
According to Oncotelic Therapeutics, Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Oncotelic Therapeutics, Inc. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
- -
CH
- -
KR